Disease · HP_0004420
Arterial thrombosis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Arterial thrombosis. Diseases, record HP_0004420. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0004420
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Arterial thrombosis
- Open Targets ID
- HP_0004420
- Other names
- Blood clot in artery
- Highest stage of its drugs
- Phase 3, for 5 of its 10 drugs, from ClinicalTrials.gov and TTD
Source Open Targets
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CLOPIDOGREL | CHEMBL1771 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| ENOXAPARIN | CHEMBL1201685 | Oligosaccharide | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OMEPRAZOLE | CHEMBL1503 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TICAGRELOR | CHEMBL398435 | Small molecule | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
| VONAPANITASE | CHEMBL3545070 | Enzyme | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
| RIVAROXABAN | CHEMBL198362 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BIVALIRUDIN | CHEMBL5314348 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIFAMPIN | CHEMBL374478 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| WARFARIN | CHEMBL1464 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets9
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| P2RY12 | P2Y purinoceptor 12 | 2 | Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/64805 | Drugs and targets |
| ATP4A | Potassium-transporting ATPase | 1 | Potassium-transporting ATPase inhibitor | Phase 3 | https://conductscience.org/library/genes/495 | Drugs and targets |
| ATP4B | Potassium-transporting ATPase | 1 | Potassium-transporting ATPase inhibitor | Phase 3 | https://conductscience.org/library/genes/496 | Drugs and targets |
| ELN | Elastin | 1 | Elastin proteolytic enzyme | Phase 3 | https://conductscience.org/library/genes/2006 | Drugs and targets |
| F10 | Coagulation factor X | 1 | Coagulation factor X inhibitor | Phase 2 | https://conductscience.org/library/genes/2159 | Drugs and targets |
| F2 | Prothrombin | 1 | Thrombin inhibitor | Phase 2 | https://conductscience.org/library/genes/2147 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Unknown | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Unknown | https://conductscience.org/library/genes/5743 | Drugs and targets |
| VKORC1 | Vitamin K epoxide reductase complex subunit 1 | 1 | Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor | Unknown | https://conductscience.org/library/genes/79001 | Drugs and targets |
Trials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04504032 | A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19) | Phase 2 | 497 | 2021-10-22 | COVID-19 | RIVAROXABAN | Its record names the disease | ClinicalTrials.gov |
| NCT02564718 | Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates | Phase 1/2 | 10 | 2018-07-10 | Thromboembolism | RIVAROXABAN | Its record names the disease | ClinicalTrials.gov |
| NCT04345848 | Preventing COVID-19 Complications With Low- and High-dose Anticoagulation | Phase 3 | 160 | COVID, Sars-CoV2 | ENOXAPARIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05646394 | Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS | 150 | Antiphospholipid Syndrome, Arterial Thrombosis | ASPIRIN, CLOPIDOGREL, WARFARIN | Its record names the disease | ClinicalTrials.gov | ||
| NCT00349661 | Influence Of Omeprazole On The Anti-Platelet Action Of Clopidogrel | Phase 3 | 120 | Coronary Heart Disease | CLOPIDOGREL, OMEPRAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT00115375 | Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO) | Phase 2 | 92 | Congenital Heart Defects, Blood Platelet Disorders | CLOPIDOGREL | Its record names the disease | ClinicalTrials.gov | |
| NCT00043277 | Study Of Angiomax In Infants Under Six Months With Thrombosis | Phase 2 | 25 | Thrombosis | BIVALIRUDIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00696566 | Healthy Volunteer Study of Clopidogrel and Rifampicin | Phase 1 | 12 | Coronary Artery Disease | CLOPIDOGREL, RIFAMPIN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials8
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Rivaroxaban vs Placebo: Number of Participants With AEs Resulting in Study Intervention Discontinuation Through Day 35 | 4 of 219 | 5 of 230 | 449 | NCT04504032 | Trial comparisons |
| Rivaroxaban vs Placebo: Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) Through Day 35 | 6 of 219 | 13 of 230 | 449 | NCT04504032 | Trial comparisons |
| Rivaroxaban vs Placebo: Number of Participants With Serious Adverse Events Through Day 35 | 2 of 219 | 7 of 230 | 449 | NCT04504032 | Trial comparisons |
| Rivaroxaban vs Placebo: deaths from any cause | 0 of 219 | 0 of 230 | 449 | NCT04504032 | Trial comparisons |
| Rivaroxaban vs Placebo: serious adverse events | 2 of 219 | 7 of 230 | 449 | NCT04504032 | Trial comparisons |
| Rivaroxaban vs Placebo: Number of Participants Who Progressed to Moderate or Severe Disease or Higher Based on the Gates MRI Ordinal Scale Through Day 28 | 46 of 222 | 44 of 222 | 444 | NCT04504032 | Trial comparisons |
| Rivaroxaban (BAY59-7939) Suspension Bid vs Rivaroxaban (BAY59-7939) Suspension Tid: deaths from any cause | 0 of 5 | 0 of 5 | 10 | NCT02564718 | Trial comparisons |
| Rivaroxaban (BAY59-7939) Suspension Bid vs Rivaroxaban (BAY59-7939) Suspension Tid: serious adverse events | 0 of 5 | 1 of 5 | 10 | NCT02564718 | Trial comparisons |
Papers from its trials8
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0004420
GET https://conductscience.org/api/diseases/v1/HP_0004420/drugs